- The NEXUS Clinical Study in cALD
The NEXUS clinical trial is a phase 2, open-label clinical study that has been designed to assess the efficacy and safety of leriglitazone in male pediatric patients with early stage cerebral X-linked adrenoleukodystrophy (cALD).
The NEXUS study recruits cALD patients with early cerebral MRI lesions. All patients will be receiving leriglitazone and they will be carefully monitored for safety, clinical symptoms and changes in cerebral MRI lesions. The study has been designed with input from both EMA and FDA, as well as EU and US clinical experts in X-ALD and patient advocacy groups. The study design does not interfere with the current Standard of Care and does not delay HSCT therapy if it becomes indicated.
For further information visit:
https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000654-59Hospitals involved in NEXUS Clinical StudySee mapUniversity Medical Center Hamburg-EppendorfHamburgGermanyHospital Sant Joan de DéuBarcelonaSpainHospitals involved in NEXUS Clinical StudySee listUniversity Medical Center Hamburg-EppendorfHamburgGermanyHospital Sant Joan de DéuBarcelonaSpain